Treatment related factors and inhibitor development in children with severe haemophilia A

Haemophilia

Volumn 17, Issue 2, 2011, Pages 282-287

  Maclean, P S ^a   Richards, M ^b   Williams, M ^c   Collins, P ^d   Liesner, R ^e   Keeling, D M ^f   Yee, T ^g   Will, A M ^h   Young, D ⁱ   Chalmers, E A ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Haemophilia A; Inhibitor; Risk factors; Treatment factors; Treatment intensity

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; PLASMA DERIVED FACTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

AFRICAN CARIBBEAN; ARTICLE; ASIAN; BRAIN HEMORRHAGE; CASE CONTROL STUDY; CAUCASIAN; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FAMILY HISTORY; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; GENETIC DISORDER; HEMOPHILIA A; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MUSCLE BLEEDING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD;

AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FACTOR VIII; GENOTYPE; HEMOPHILIA A; HUMANS; INFANT; MULTIVARIATE ANALYSIS; MUTATION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79951778636     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02422.x     Document Type: Article

References (14)

1. Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia 2004; 10: 63-8.
2. Hay CR, Hay CRM. The epidemiology of factor VIII inhibitors. Haemophilia 2006; 12(Suppl. 6): 23-9. Discussion 8-9.
3. Astermark J, Berntorp E, White GC, Kroner BL, Group MS. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
4. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
5. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5: 1383-90.
6. White GC 2nd, Rosendaal F, Aledort LM et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
7. Goodeve AC, Williams I, Bray GL, Peake IR. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thromb Haemost 2000; 83: 844-8.
8. Chalmers EA, Brown SA, Keeling D et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
9. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
10. Gouw SC, van der Bom JG, Auerswald G et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7.
11. Halimeh S, Bindlingmaier C, Escuriola Ettinghausen C et al. Evidence for increased inhibitor incidence in children with severe hemophilia a treated with recombinant factor VIII products: a systematic review & meta-analysis. J Thromb Haemost 2009; 7: 247.
12. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-7.
13. Morado M, Villar A, Jimenez YV, Quintana M, Hernandez NF. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005; 11(2): 79-83.
14. Calvez T, Laurian Y, Calvez T, Laurian Y. Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required. Br J Haematol 2006; 132: 798-800. author reply - 1.